Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]) - White, Harvey D; Bhatt, Deepak L; Gibson, C Michael; Hamm, Christian W; Mahaffey, Kenneth W; Price, Matthew J; Steg, Ph Gabriel; Stone, Gregg W; Cortese, Bernardo; Wilensky, Michael; Deliargyris, Efthymios N; Liu, Tiepu; et al. (JACC. Cardiovascular interventions, 2015)
Keywords: Adenosine Monophosphate - adverse effects; Adenosine Monophosphate - analogs & derivatives; Adenosine Monophosphate - therapeutic use; Aged; Anticoagulants - adverse effects; Anticoagulants - therapeutic use; Chi-Square Distribution; Coronary Artery Disease - diagnosis; Coronary Artery Disease - mortality; Coronary Artery Disease - therapy; Coronary Thrombosis - etiology; Coronary Thrombosis - prevention & control; Double-Blind Method; Female; Hemorrhage - chemically induced; Hirudins - adverse effects; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction - etiology; Myocardial Infarction - prevention & control; Odds Ratio; Peptide Fragments - adverse effects; Peptide Fragments - therapeutic use; Percutaneous Coronary Intervention - adverse effects; Percutaneous Coronary Intervention - instrumentation; Percutaneous Coronary Intervention - mortality; Platelet Aggregation Inhibitors - adverse effects; Platelet Aggregation Inhibitors - therapeutic use; Recombinant Proteins - adverse effects; Recombinant Proteins - therapeutic use; Risk Factors; Stents; Ticlopidine - adverse effects; Ticlopidine - analogs & derivatives; Ticlopidine - therapeutic use; Time Factors; Treatment Outcome; CHAMPION PHOENIX; cangrelor; bivalirudin; stent thrombosis